Literature DB >> 35241555

Immunostimulation and Coagulopathy in COVID-19 Compared to Patients With H1N1 Pneumonia or Bacterial Sepsis.

Dimitrios-Dorotheos Papadakis1, Marianna Politou2, Maria Kompoti3, Dimitrios Vagionas1, Eirini Kostakou1, Danai Theodoulou1, Evangelos Kaniaris1, Nikoletta Rovina1, George Panayiotakopoulos4, Stavros Dimopoulos5, Antonia Koutsoukou1, Ioannis Vasileiadis6.   

Abstract

BACKGROUND/AIM: Multiple reports from all over the world link COVID-19 with endothelial/coagulation disorders as well as a dysregulated immune response. This study tested the hypothesis that immunostimulation will be greater in COVID-19 patients than in patients with H1N1 infection or bacterial sepsis. Also, whether an increase in immune stimulation will be accompanied by a more severely affected endothelium/coagulation system was examined. PATIENTS AND METHODS: Twenty-three septic patients, admitted in the Intensive Care Unit (ICU), were enrolled (9 with SARS-CoV-2, 5 with H1N1 pneumonia, 9 with bacterial sepsis). Myeloperoxidase (MPO) activity along with certain endothelial/coagulation factors were assessed on admission (time point 1) and at either improvement or deterioration (time point 2).
RESULTS: MPO levels were significantly higher in COVID-19 patients compared to both other groups. Furthermore, in patients with COVID-19, vWF levels did not differ significantly, fVIII levels were lower while ADAMTS-13 activity was higher compared to patients with H1N1 pneumonia and bacterial sepsis (a trend in the latter).
CONCLUSION: Increased immunostimulation was noted in COVID-19 patients compared to other septic patients; however, this was not accompanied by greater disturbance of the clotting system and/or more severe endothelial injury.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  ADAMTS-13; Innate immunity; SARS-CoV-2; coagulopathy in COVID-19

Mesh:

Year:  2022        PMID: 35241555      PMCID: PMC8931926          DOI: 10.21873/invivo.12786

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  20 in total

1.  Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system.

Authors:  Joshua M Astern; William F Pendergraft; Ronald J Falk; J Charles Jennette; Alvin H Schmaier; Fakhri Mahdi; Gloria A Preston
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

2.  Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.

Authors:  Sachin Yende; Gina D'Angelo; John A Kellum; Lisa Weissfeld; Jonathan Fine; Robert D Welch; Lan Kong; Melinda Carter; Derek C Angus
Journal:  Am J Respir Crit Care Med       Date:  2008-03-27       Impact factor: 21.405

3.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

Review 4.  Myeloperoxidase: friend and foe.

Authors:  Seymour J Klebanoff
Journal:  J Leukoc Biol       Date:  2005-02-02       Impact factor: 4.962

Review 5.  Thrombosis as an intravascular effector of innate immunity.

Authors:  Bernd Engelmann; Steffen Massberg
Journal:  Nat Rev Immunol       Date:  2012-12-07       Impact factor: 53.106

6.  Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps.

Authors:  Venizelos Papayannopoulos; Kathleen D Metzler; Abdul Hakkim; Arturo Zychlinsky
Journal:  J Cell Biol       Date:  2010-10-25       Impact factor: 10.539

7.  Endothelial cell infection and endotheliitis in COVID-19.

Authors:  Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch
Journal:  Lancet       Date:  2020-04-21       Impact factor: 79.321

8.  COVID19 coagulopathy in Caucasian patients.

Authors:  Helen Fogarty; Liam Townsend; Cliona Ni Cheallaigh; Colm Bergin; Ignacio Martin-Loeches; Paul Browne; Christopher L Bacon; Richard Gaule; Alexander Gillett; Mary Byrne; Kevin Ryan; Niamh O'Connell; Jamie M O'Sullivan; Niall Conlon; James S O'Donnell
Journal:  Br J Haematol       Date:  2020-05-17       Impact factor: 8.615

9.  Hematological findings and complications of COVID-19.

Authors:  Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Ismail Elalamy; Efstathios Kastritis; Theodoros N Sergentanis; Marianna Politou; Theodora Psaltopoulou; Grigoris Gerotziafas; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2020-05-23       Impact factor: 13.265

View more
  1 in total

Review 1.  Venous Thromboembolism in Sepsis: From Bench to Bedside.

Authors:  Eleonora Galli; Elena Maggio; Fulvio Pomero
Journal:  Biomedicines       Date:  2022-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.